Supplementary Figure 1 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes

• DOI: 10.1158/2326-6066.26144579.v1
• Publication Date: 2024-07-02T07:28:44Z
• Authors: David König; Michael T. Sandho...; Sarp Uzun; Andreas Zingg; Reto Ritschard; Helen Thut; Katharina Glatz; Elisabeth A. Kappos; Dirk J. Schaefer; Christoph Kettelhack; Jakob R. Passweg; Andreas Holbro; Katharina Baur; Michael Medinger; Andreas Buser; Didier Lardinois; Lukas T. Jeker; Nina Khanna; Frank Stenner; Benjamin Kasenda; Krisztian Homicsko; Matthias Matter; Natalia Rodrigues...; Alfred Zippelius; Heinz Läubli
• Keywords: Tumor-infiltrating lymphocytes; Adoptive Cell Transfer

<p>Supplementary Figure 1. Study Design of the <i>BaseTIL</i> trial. The trial was a phase I tumor-infiltrating lymphocyte (TIL) therapy in combination with low dose interleukin-2 (IL2) and PD1 blockade nivolumab for patients metastatic melanoma.</p>